Atogepant Preferred Over Topiramate in New Migraine Study

• Atogepant showed superior tolerability with fewer adverse event-related discontinuations.
• Supports CGRP inhibitors as first-line migraine preventive treatment options.
• Improved patient adherence through combined efficacy and tolerability benefits.

When comparing the tolerability, safety, and effectiveness of atogepant to the highest tolerated dose of topiramate in adult patients with a history of four or more migraine days per month.  AbbVie reported positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, and head -to-head study.

By showing that atogepant, an antagonist of the calcitonin gene-related peptide(CGRP) receptor, had fewer treatment discontinuations due to adverse events (AEs) than topiramate, an anticonvulsant drug also authorized for the prevention of migraines, the study achieved its primary endpoint.

"These TEMPLE data affirm recommendations from the American Headache Society and International Headache Society, highlighting the role of CGRP pathway inhibitors as first-line preventive treatment options for migraine," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie.

Also Read: Encube Opens Advanced Life Sciences R&D Centre at Palava

"Far too often, people living with migraine struggle with meeting their treatment goals despite available and accessible preventive options," said Jaclyn Duvall, M.D., neurologist and founder of Headache Specialists of Oklahoma. "The TEMPLE data provide a patient-centered measure of treatment effectiveness by capturing both efficacy and tolerability, representing a meaningful way to evaluate the real-world impact of treatment persistence in migraine prevention."